Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Medipharm Labs Corp T.LABS

Alternate Symbol(s):  MEDIF

MediPharm Labs Corp. is a Canada-based full-service pharmaceutical company. The Company specializes in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API) and advanced derivative products. Through its wholesale and white label platforms, the Company formulates, develops (including through sensory testing), processes, packages and distributes cannabis extracts and advanced cannabinoid-based products to domestic and international markets. It also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, it cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. It also sells metered dose inhalers and aerosol sublingual sprays. Through Harvest Medicine, it provides clinic services to Canadian patients requiring medical cannabis education and prescriptions.


TSX:LABS - Post by User

Comment by rusty777on May 22, 2024 3:44pm
102 Views
Post# 36052635

RE:Investor attitude toward management

RE:Investor attitude toward managementI think many of the investors here are well beyond frustrated.  For those who originally owned ABCANN which became VIVO, which was absorbed into Medipharm, we have seen management time and time again ensure their own benefit/prosperity before the shareholders.  Even now the senior management positions command a compensation well above the industry average for similar sized companies.  For most of us our investment is now only worth 1 - 2 cents on the dollar of what was initially invested so probably not worth selling and similarily probably never going to be worth much more than we are seeing right now.  Simply Wall Street has their free cashflow at -11.3 million and senior management compensation (or at least what they can estimate as a 4 of the 8 senior management positions are currenly listed as "no data") is in excess of 6.7 million.

That suggests that the likelihood of shareholders seeing any increase in equity is rather slim at the moment.

But hey - maybe they will all take a pay cut for the good of the company.

GLTA

Rusty


<< Previous
Bullboard Posts
Next >>